We observed that the MYC/KRAS chimeric siRNA combined with an approved KRASG12C small-molecule inhibitor led to highly significant and durable reductions in tumor size, including some complete regressions, suggesting that combination approaches that cotarget KRAS at the mRNA and protein levels may be advantageous. The gene discussed is KRAS; the disease is neoplasm.